FOXO4-DRI Dosage: There Is No Human Dose to Give You
Summary: Every dosage chart for this compound was written by someone extrapolating from rodent experiments, and the vial they were extrapolating into does not reliably contain what its label says.
This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.
FOXO4-DRI dosage has no established human answer, and it is better to say that in the first sentence than to bury it under a chart. No human being has received this peptide in a registered clinical trial. There is no approved dose, no tolerability ceiling, and no measurement of how the compound behaves in a person.
Where readers actually buy it
Ascension Peptides — FOXO4-DRI
Research-grade FOXO4-DRI, tested by two outside labs and shipped from the US. The code below takes half off the vial.
The two published certificates cover different batches and disagree on net content: Kovera Labs assayed batch 55-05260628 at 11.41 mg and MZ Biolabs assayed lot 55-01260229 at 8.30 mg, both against a 10 mg label, which moves the real figure between $5.87 and $8.07/mg. Endotoxin and sterility screens appear on the Kovera batch only. The vendor spells the product FOX04 with a zero, including in the link. Buying 3, 5 or 10 takes 3%, 5% or 10% off the list price. Free shipping starts at $250.
- Batch certificates from two independent labs
- Free shipping over $250
- Ships same day if ordered before 2pm CST
Sold for laboratory research only and not for human consumption. FOXO4-DRI is not an approved medicine in any market and has never been tested in a human trial. These are affiliate links: we may earn a commission at no cost to you, and it does not change what we recommend. Prices checked September 2, 2026.
Why "no established dose" is the accurate answer
Readers of this site are used to the idea that a dose is a known quantity, because for semaglutide or tirzepatide it is. That number exists because a specific sequence of work produced it.
Phase 1 trials establish how a compound is absorbed, distributed, metabolised and cleared in humans, and what dose begins to cause unacceptable effects. Phase 2 finds the range where benefit appears. Phase 3 confirms it at scale. A regulator reviews all of it and approves a label. The number on that label is the output of the entire process.
For FOXO4-DRI none of that has happened [2]. There is no measured human half-life, no bioavailability figure, no clearance route, no maximum tolerated dose, and no adverse-event dataset. A dosing chart in that situation is not a summary of evidence; it is a piece of writing.
What the published animal work used
For completeness, because the question deserves a real answer rather than a refusal.
In the foundational 2017 study, mice received FOXO4-DRI at 5 mg/kg, three times on alternating days, on days 1, 3 and 5. Administration was intravenous in the chemotoxicity experiments and intraperitoneal in the ageing cohorts. Doxorubicin, used to drive cells into senescence in that model, was given separately at 10 mg/kg in mice [1].
Two features of that schedule are consistently misreported. It was intermittent, three doses across five days rather than an ongoing course, because a senolytic aims to clear a cell population and then stop. And the routes used, intravenous and intraperitoneal, are laboratory routes in laboratory animals; intraperitoneal injection is not a route used in human medicine outside narrow clinical circumstances.
Why a mouse figure does not convert
The obvious move is to take 5 mg/kg, multiply by body weight, apply a scaling factor and produce a number. Interspecies allometric scaling is a genuine method, but it estimates a starting point for further study, not a usable dose, and it requires inputs this compound does not have.
Scaling assumes you know how a compound is handled by the target species. For FOXO4-DRI in humans, nothing is known: no half-life, no bioavailability, no clearance, no distribution volume. A D-retro-inverso peptide is specifically engineered to resist protease degradation, which is likely to change its persistence relative to an ordinary peptide, and by how much in a human body is unstudied.
There is also the question of what you would be aiming at. The mouse experiments measured senescent-cell clearance in particular tissues under particular stressors. The relationship between a dose that clears senescent cells in a mouse liver and any human outcome has never been established, because no human outcome has been measured.
So the arithmetic can be performed. It does not produce knowledge.
The problem that is actually checkable
Here is where something concrete can be said, and it is the part most pages miss entirely.
Reconstitution arithmetic is simple: mass divided by volume gives concentration. The difficulty is the mass, because for this product the label and the laboratory reports disagree.
Kovera Labs certified batch 55-05260628 at 99.411% purity with net content of 11.41 mg. MZ Biolabs analysed lot 55-01260229 at 99.97% purity with net content of 8.30 mg. Both vials were labelled 10 mg, and both were excellent on purity, because purity and quantity are separate measurements.
| Starting mass | In 1 mL | In 2 mL | In 3 mL |
|---|---|---|---|
| 10 mg, from the label | 10.00 mg/mL | 5.00 mg/mL | 3.33 mg/mL |
| 11.41 mg, Kovera batch | 11.41 mg/mL | 5.71 mg/mL | 3.80 mg/mL |
| 8.30 mg, MZ Biolabs lot | 8.30 mg/mL | 4.15 mg/mL | 2.77 mg/mL |
Anyone holding the January batch and calculating from the label carries a concentration error of roughly 17%, and every volume drawn inherits it. No amount of careful measurement downstream corrects a wrong starting mass. Use the net content from the certificate matching your lot, and if you were not given a lot-matched certificate, ask for one. The peptide calculator does the conversion correctly once the input is right.
Handling, which is not dosing
The lyophilised powder is the stable form, which is why it ships dry and why a warm parcel is not a spoiled one. Kept cool, dark and sealed, dry peptide is comparatively durable.
Bacteriostatic water, not sterile water, is what permits repeated withdrawals, because it contains a preservative. Direct solvent against the vial wall and swirl rather than shake; agitation denatures peptides and visible foaming is evidence of it. Reconstituted material belongs refrigerated, protected from light, and used within a much shorter window than the dry powder allowed.
One further reason for caution: senolysis is not uniformly beneficial. Senescent cells suppress tumour formation and contribute to wound healing, and a 2023 study found clearing them could worsen pulmonary hypertension [3]. The absence of a human dose sits alongside an absence of human safety data.
- What is the correct FOXO4-DRI dosage?
- There is no correct human dosage, because the compound has never been tested in a registered human trial. No regulator has reviewed it, no phase 1 study has established tolerability, and no human pharmacokinetic data exists.
- What dose did the mouse studies use?
- 5 mg/kg, three times on alternating days, days 1, 3 and 5, intravenously in the chemotoxicity experiments and intraperitoneally in the ageing cohorts. Those are mouse doses via laboratory routes.
- Can I convert the mouse dose using body-weight scaling?
- You can perform the calculation, but it does not yield a validated dose. Allometric scaling estimates a starting point for formal study and requires pharmacokinetic inputs that do not exist for this peptide in humans.
- How much peptide is actually in a 10 mg vial?
- It varies by batch. The two published certificates measured 11.41 mg and 8.30 mg against the same 10 mg label. Work from the certificate matching your lot number, because the label assumption can put a concentration out by roughly 17%.
- How should reconstituted FOXO4-DRI be stored?
- Refrigerated, protected from light, and not agitated. Bacteriostatic water rather than sterile water allows repeated withdrawals. The dry powder is far more stable, so material is best left lyophilised until use.